CORAL SPRINGS, FL--(Marketwired - Nov 18, 2013) - Nutra Pharma Corp. (
"This conference provides an excellent opportunity to expand our presence within the investment community and share our unique and exciting growth story," commented Rik J Deitsch, CEO of Nutra Pharma. "We first presented at the Undiscovered Equities Conferences in 2009 when we launched our first retail product, Cobroxin. That conference created a lot of excitement among our investors and we hope to emulate that at this and future conferences," he concluded.
Undiscovered Equities is a provider of equity research on high-impact aggressive growth investment opportunities. Their services include research analysis on the energy and precious metals markets, news and financial data, market commentary and the Undiscovered Equities newsletter. Their Fall Conference includes a full day of presentations at Ruth's Chris Steakhouse in Boca Raton, Florida on November 21, 2013 from 8:30am through 4:00pm followed by a nighttime reception. Nutra Pharma is scheduled to present at approximately 10:30am. For more information on Undiscovered Equities, visit:
Nutra Pharma recently announced the expansion of marketing and distribution of their Nyloxin® products, the re-launch of Cobroxin® as well as the initial launch of Pet Pain-Away for pain in companion animals and Equine Nyloxin® for pain in horses. The Company is looking forward to the expanded marketing campaign for Nyloxin® by their distributor, New Vitality and the launch of the first Nyloxin® television commercials by the end of the year.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The presentation at this conference should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.